Gut and Liver

The Korean Association for the Study of the Liver (대한간학회)
권호 표지
DOI QR코드

DOI QR Code

Inflammatory Bowel Disease in Korea: Epidemiological, Genomic, Clinical, and Therapeutic Characteristics

  • Kim, Eun-Soo (Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine) ;
  • Kim, Won-Ho (Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine)
  • Published : 2010.03.30
⟨ Previous Next ⟩

Abstract

Inflammatory bowel disease (IBD) describes chronic inflammatory disease of the intestines and has a variable course; Crohn's disease and ulcerative colitis comprise the two main forms of the condition. Although IBD occurs worldwide, its epidemiologic and clinical characteristics vary depending upon the geographic location and the ethnicity of the population. Identifying the characteristic features of IBD in populations living in different geographical locations and with different ethnicities may provide significant clues about its etiology and pathophysiology, which in turn may be helpful in the development of more appropriate treatment strategies for IBD for these different populations. Therefore, it is important for each country and region to evaluate critically the epidemiology, genomics, and clinical characteristics of IBD among its own population. We have performed a critical review of the recent data in Korea, and describe herein the current epidemiologic and genotypic status, as well as the clinical manifestations and therapeutic responses of IBD that are unique to Korean patients.

Keywords

References

  1. Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis 2008;14:542-549. https://doi.org/10.1002/ibd.20310
  2. Leong RW, Lau JY, Sung JJ. The epidemiology and phenotype of Crohn's disease in the Chinese population. Inflamm Bowel Dis 2004;10:646-651. https://doi.org/10.1097/00054725-200409000-00022
  3. Morita N, Toki S, Hirohashi T, et al. Incidence and prevalence of inflammatory bowel disease in Japan: nationwide epidemiological survey during the year 1991. J Gastroenterol 1995;30 Suppl 8:1-4.
  4. Yang SK, Hong WS, Min YI, et al. Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong District, Seoul, Korea, 1986-1997. J Gastroenterol Hepatol 2000;15:1037-1042. https://doi.org/10.1046/j.1440-1746.2000.02252.x
  5. Ling KL, Ooi CJ, Luman W, Cheong WK, Choen FS, Ng HS. Clinical characteristics of ulcerative colitis in Singapore, a multiracial city-state. J Clin Gastroenterol 2002;35:144-148. https://doi.org/10.1097/00004836-200208000-00005
  6. Iida M, Yao T, Okada M. Long-term follow-up study of Crohn's disease in Japan: the Research Committee of Inflammatory Bowel Disease in Japan. J Gastroenterol 1995;30 Suppl 8:17-19.
  7. Inoue N, Tamura K, Kinouchi Y, et al. Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology 2002;123:86-91. https://doi.org/10.1053/gast.2002.34155
  8. Yang SK, Loftus EV Jr, Sandborn WJ. Epidemiology of inflammatory bowel disease in Asia. Inflamm Bowel Dis 2001;7:260-270. https://doi.org/10.1097/00054725-200108000-00013
  9. Kim BJ, Yang SK, Kim JS, et al. Trends of ulcerative colitis- associated colorectal cancer in Korea: a KASID study. J Gastroenterol Hepatol 2009;24:667-671. https://doi.org/10.1111/j.1440-1746.2008.05730.x
  10. Chang DK, Kim YH, Byeon JS, et al. The current status of ulcerative colitis-associated colorectal cancer in Korea: a KASID study. Korean J Gastroenterol 2005;46:276-282.
  11. Cheon JH, Kim JH, Kim BY, et al. Allele frequency of thiopurine methyltransferase and inosine triphosphate pyrophosphatase gene polymorphisms in Korean patients with inflammatory bowel diseases. Hepatogastroenterology 2009;56:421-423.
  12. Lee SK, Kim BK, Kim TI, Kim WH. Differential diagnosis of intestinal Behcet's disease and Crohn's disease by colonoscopic findings. Endoscopy 2009;41:9-16. https://doi.org/10.1055/s-0028-1103481
  13. Kim JY, Yang SK, Byeon JS. The incidence and natural history of perianal fistulas in Korean patients with Crohn's disease. Intest Res 2006;4:22-31.
  14. Ko YT, Kim NK, Min BS, et al. Twenty cases of restorative proctocolectomy for ulcerative colitis of Asian patients: analysis of operative safety and functional outcomes in single institution experience. Int J Colorectal Dis 2008;23:131-132.
  15. Lee GH, Kim CG, Kim JS, Jung HC, Song IS. Frequency analysis of NOD2 gene mutations in Korean patients with Crohn's disease. Korean J Gastroenterol 2005;45:162-168.
  16. Lee H, Kim YH, Kim JH, et al. Nonsurgical treatment of abdominal or pelvic abscess in consecutive patients with Crohn's disease. Dig Liver Dis 2006;38:659-664. https://doi.org/10.1016/j.dld.2005.12.001
  17. Lee JH, Cheon JH, Kim ES, et al. The prevalence and clinical significance of perinuclear anti-neutrophil cytoplasmic antibody in Korean patients with ulcerative colitis. Dig Dis Sci. Forthcoming. DOI: 10.1007/s10620-009-0847-8.
  18. Lee YJ, Yang SK, Byeon JS, et al. Analysis of colonoscopic findings in the differential diagnosis between intestinal tuberculosis and Crohn's disease. Endoscopy 2006;38:592-597. https://doi.org/10.1055/s-2006-924996
  19. Park JJ, Cheon JH, Kim BY, et al. Correlation of serum-soluble triggering receptor expressed on myeloid cells-1 with clinical disease activity in inflammatory bowel disease. Dig Dis Sci 2009;54:1525-1531. https://doi.org/10.1007/s10620-008-0514-5
  20. Park SH, Kim YM, Yang SK, et al. Clinical features and natural history of ulcerative colitis in Korea. Inflamm Bowel Dis 2007;13:278-283. https://doi.org/10.1002/ibd.20015
  21. Russel MG. Changes in the incidence of inflammatory bowel disease: what does it mean? Eur J Intern Med 2000;11:191-196. https://doi.org/10.1016/S0953-6205(00)00090-X
  22. Cashman KD, Shanahan F. Is nutrition an aetiological factor for inflammatory bowel disease? Eur J Gastroenterol Hepatol 2003;15:607-613. https://doi.org/10.1097/00042737-200306000-00005
  23. Jovanovic Z. Epidemiology of Crohn's disease in the Rijeka-Istra region. Lijec Vjesn 1999;121:8-13.
  24. Appleyard CB, Hernandez G, Rios-Bedoya CF. Basic epidemiology of inflammatory bowel disease in Puerto Rico. Inflamm Bowel Dis 2004;10:106-111. https://doi.org/10.1097/00054725-200403000-00007
  25. Linares de la Cal JA, Canton C, Hermida C, Perez-Miranda M, Mate-Jimenez J. Estimated incidence of inflammatory bowel disease in Argentina and Panama (1987-1993). Rev Esp Enferm Dig 1999;91:277-286.
  26. Lakatos L, Mester G, Erdelyi Z, et al. Striking elevation in incidence and prevalence of inflammatory bowel disease in a province of western Hungary between 1977-2001. World J Gastroenterol 2004;10:404-409.
  27. Sincic BM, Vucelic B, Persic M, et al. Incidence of inflammatory bowel disease in Primorsko-goranska County, Croatia, 2000-2004: a prospective population-based study. Scand J Gastroenterol 2006;41:437-444. https://doi.org/10.1080/00365520500320094
  28. Molinie F, Gower-Rousseau C, Yzet T, et al. Opposite evolution in incidence of Crohn's disease and ulcerative colitis in Northern France (1988-1999). Gut 2004;53:843-848. https://doi.org/10.1136/gut.2003.025346
  29. Lapidus A. Crohn's disease in Stockholm County during 1990-2001: an epidemiological update. World J Gastroenterol 2006;12:75-81.
  30. Loftus EV Jr, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology 1998;114:1161-1168. https://doi.org/10.1016/S0016-5085(98)70421-4
  31. Loftus EV Jr, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut 2000;46:336-343. https://doi.org/10.1136/gut.46.3.336
  32. Bernstein CN, Wajda A, Svenson LW, et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 2006;101:1559-1568. https://doi.org/10.1111/j.1572-0241.2006.00603.x
  33. Gearry RB, Richardson A, Frampton CM, et al. High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm Bowel Dis 2006;12:936-943. https://doi.org/10.1097/01.mib.0000231572.88806.b9
  34. Yao T, Matsui T, Hiwatashi N. Crohn's disease in Japan: diagnostic criteria and epidemiology. Dis Colon Rectum 2000;43(10 Suppl):S85-S93.
  35. Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology 2004;126:1518-1532. https://doi.org/10.1053/j.gastro.2004.02.072
  36. Park JB, Yang SK, Myung SJ, et al. Clinical characteristics at diagnosis and course of Korean patients with Crohn's disease. Korean J Gastroenterol 2004;43:8-17.
  37. Calkins BM, Lilienfeld AM, Garland CF, Mendeloff AI. Trends in incidence rates of ulcerative colitis and Crohn's disease. Dig Dis Sci 1984;29:913-920. https://doi.org/10.1007/BF01312480
  38. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989;170:2-6.
  39. Myren J, Bouchier IA, Watkinson G, Softley A, Clamp SE, de Dombal FT. The OMGE multinational inflammatory bowel disease survey 1976-1986: a further report on 3175 cases. Scand J Gastroenterol Suppl 1988;144:11-19.
  40. Saxon A, Shanahan F, Landers C, Ganz T, Targan S. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 1990;86:202-210. https://doi.org/10.1016/S0091-6749(05)80067-3
  41. Vermeire S, Joossens S, Peeters M, et al. Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology 2001;120:827-833. https://doi.org/10.1053/gast.2001.22546
  42. Kim BG, Kim YS, Kim JS, Jung HC, Song IS. Diagnostic role of anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic antibodies in patients with inflammatory bowel disease. Dis Colon Rectum 2002;45:1062-1069. https://doi.org/10.1007/s10350-004-6361-3
  43. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603. https://doi.org/10.1038/35079107
  44. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-606. https://doi.org/10.1038/35079114
  45. Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001;357:1925-1928. https://doi.org/10.1016/S0140-6736(00)05063-7
  46. Stoll M, Corneliussen B, Costello CM, et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet 2004;36:476-480. https://doi.org/10.1038/ng1345
  47. Till A, Rosenstiel P, Krippner-Heidenreich A, et al. The Met-196 $\rightarrow$ Arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha-induced apoptosis by impaired NF-kappaB signaling and target gene expression. J Biol Chem 2005;280:5994-6004.
  48. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461-1463. https://doi.org/10.1126/science.1135245
  49. Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007;39:207-211. https://doi.org/10.1038/ng1954
  50. Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007;39:596-604. https://doi.org/10.1038/ng2032
  51. Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet 2007;39:830-832. https://doi.org/10.1038/ng2061
  52. Raelson JV, Little RD, Ruether A, et al. Genome-wide association study for Crohn's disease in the Quebec Founder Population identifies multiple validated disease loci. Proc Natl Acad Sci U S A 2007;104:14747-14752. https://doi.org/10.1073/pnas.0706645104
  53. Riis L, Vind I, Vermeire S, et al. The prevalence of genetic and serologic markers in an unselected European population- based cohort of IBD patients. Inflamm Bowel Dis 2007;13:24-32. https://doi.org/10.1002/ibd.20047
  54. Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 2005;128:2020-2028. https://doi.org/10.1053/j.gastro.2005.03.046
  55. Braun J, Targan SR. Multiparameter analysis of immunogenetic mechanisms in clinical diagnosis and management of inflammatory bowel disease. Adv Exp Med Biol 2006;579:209-218. https://doi.org/10.1007/0-387-33778-4_13
  56. Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology 2007;133:1670-1689. https://doi.org/10.1053/j.gastro.2007.09.001
  57. Oriuchi T, Hiwatashi N, Kinouchi Y, et al. Clinical course and longterm prognosis of Japanese patients with Crohn's disease: predictive factors, rates of operation, and mortality. J Gastroenterol 2003;38:942-953. https://doi.org/10.1007/s00535-003-1177-9
  58. Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a populationbased study from the Danish Crohn colitis database. Am J Gastroenterol 2006;101:1274-1282. https://doi.org/10.1111/j.1572-0241.2006.00552.x
  59. Croucher PJ, Mascheretti S, Hampe J, et al. Haplotype structure and association to Crohn's disease of CARD15 mutations in two ethnically divergent populations. Eur J Hum Genet 2003;11:6-16. https://doi.org/10.1038/sj.ejhg.5200897
  60. Yang SK, Lee SG, Cho YK, Lim J, Lee I, Song K. Association of TNF-alpha/LTA polymorphisms with Crohn's disease in Koreans. Cytokine 2006;35:13-20. https://doi.org/10.1016/j.cyto.2006.07.002
  61. Yang SK, Lim J, Chang HS, et al. Association of TNFSF15 with Crohn's disease in Koreans. Am J Gastroenterol 2008;103:1437-1442. https://doi.org/10.1111/j.1572-0241.2007.01752.x
  62. Yang SK, Park M, Lim J, et al. Contribution of IL23R but not ATG16L1 to Crohn's disease susceptibility in Koreans. Inflamm Bowel Dis 2009;15:1385-1390. https://doi.org/10.1002/ibd.20921
  63. Yoshitake S, Kimura A, Okada M, Yao T, Sasazuki T. HLA class II alleles in Japanese patients with inflammatory bowel disease. Tissue Antigens 1999;53:350-358. https://doi.org/10.1034/j.1399-0039.1999.530405.x
  64. Masuda H, Nakamura Y, Tanaka T, Hayakawa S. Distinct relationship between HLA-DR genes and intractability of ulcerative colitis. Am J Gastroenterol 1994;89:1957-1962.
  65. Myung SJ, Yang SK, Jung HY, et al. HLA-DRB1*1502 confers susceptibility to ulcerative colitis, but is negatively associated with its intractability: a Korean study. Int J Colorectal Dis 2002;17:233-237. https://doi.org/10.1007/s00384-001-0381-4
  66. Satsangi J, Welsh KI, Bunce M, et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 1996;347:1212-1217. https://doi.org/10.1016/S0140-6736(96)90734-5
  67. De La Concha EG, Fernandez-Arquero M, Santa-Cruz S, et al. Positive and negative associations of distinct HLA-DR2 subtypes with ulcerative colitis (UC). Clin Exp Immunol 1997;108:392-395. https://doi.org/10.1046/j.1365-2249.1997.3951285.x
  68. Cottone M, Bunce M, Taylor CJ, Ting A, Jewell DP. Ulcerative colitis and HLA phenotype. Gut 1985;26:952-954. https://doi.org/10.1136/gut.26.9.952
  69. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2:1041-1048. https://doi.org/10.1136/bmj.2.4947.1041
  70. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-1629. https://doi.org/10.1056/NEJM198712243172603
  71. Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996;39:690-697. https://doi.org/10.1136/gut.39.5.690
  72. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98:811-818. https://doi.org/10.1016/0016-5085(90)90002-I
  73. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205. https://doi.org/10.1016/S0016-5085(98)70381-6
  74. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000;6:8-15. https://doi.org/10.1097/00054725-200002000-00002
  75. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001;49:777-782. https://doi.org/10.1136/gut.49.6.777
  76. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-753. https://doi.org/10.1136/gut.2005.082909
  77. Han JY. Clinical outcome of Crohn's disease. Korean J Gastroenterol 2002;40(Suppl 5):187A.
  78. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979;77:843-846.
  79. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002;122:512-530. https://doi.org/10.1053/gast.2002.31072
  80. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1:514.
  81. Van Hees PA, Van Lier HJ, Van Elteren PH, et al. Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study. Gut 1981;22:404-409. https://doi.org/10.1136/gut.22.5.404
  82. Anthonisen P, Barany F, Folkenborg O, et al. The clinical effect of salazosulphapyridine (Salazopyrin r) in Crohn's disease. A controlled double-blind study. Scand J Gastroenterol 1974;9:549-554.
  83. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979;77:847-869.
  84. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-266.
  85. Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol 1994;19:278-282. https://doi.org/10.1097/00004836-199412000-00003
  86. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology 1993;104:1293-1301.
  87. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004;2:379-388. https://doi.org/10.1016/S1542-3565(04)00122-3
  88. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991;32:1071-1075. https://doi.org/10.1136/gut.32.9.1071
  89. Ambrose NS, Allan RN, Keighley MR, et al. Antibiotic therapy for treatment in relapse of intestinal Crohn's disease: a prospective randomized study. Dis Colon Rectum 1985;28:81-85. https://doi.org/10.1007/BF02552649
  90. Blichfeldt P, Blomhoff JP, Myhre E, Gjone E. Metronidazole in Crohn's disease: a double blind cross-over clinical trial. Scand J Gastroenterol 1978;13:123-127. https://doi.org/10.3109/00365527809179816
  91. Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002;123:33-40. https://doi.org/10.1053/gast.2002.34225
  92. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease: Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994;331:836-841. https://doi.org/10.1056/NEJM199409293311303
  93. Tremaine WJ, Hanauer SB, Katz S, et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol 2002;97:1748-1754. https://doi.org/10.1111/j.1572-0241.2002.05835.x
  94. Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG. The effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther 2002;16:1509-1517. https://doi.org/10.1046/j.1365-2036.2002.01289.x
  95. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:935-939. https://doi.org/10.1053/j.gastro.2006.01.047
  96. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006;55(Suppl 1):i16-i35.
  97. Hyun JG, Kim JJ, Kim YH, et al. Analysis of clinical, biochemical and pathologic factors according to the response to initial steroid therapy in active Crohn's disease. Korean J Gastrointest Endosc 2001;22:406-410.
  98. Kim DH. Response rate to oral steroid therapy in patients with Crohn's disease and its clinical predictive factors [master's thesis]. Seoul: Yonsei University, 2009.
  99. Lee KM, Kim JS, Ye BD, et al. Infliximab treatment in Crohn's disease: a nation-wide survey in Korea. Paper presented at: The 3rd Japan-Korea IBD symposium; 2008 Sep 20; Seoul, Korea.
  100. Health Insurance Review and Assessment Service [Internet]. Seoul: Health Insurance Review and Assessment Service, c2009. Available from: http://www.hira.or.kr/.
  101. Ahn HS, Lee SK, Kim HJ, et al. Risk of postoperative infection in patients with inflammatory bowel disease. Korean J Gastroenterol 2006;48:306-312.
  102. Sandborn WJ, Lofberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 2005;100:1780-1787. https://doi.org/10.1111/j.1572-0241.2005.41992.x
  103. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med 1980;302:981-987. https://doi.org/10.1056/NEJM198005013021801
  104. Hanauer SB, Sandborn W. Management of Crohn's disease in adults. Am J Gastroenterol 2001;96:635-643. https://doi.org/10.1111/j.1572-0241.2001.03671.x
  105. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674-678. https://doi.org/10.1136/gut.37.5.674
  106. Lemann M, Mary JY, Colombel JF, et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005;128:1812-1818. https://doi.org/10.1053/j.gastro.2005.03.031
  107. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 2005;20:1149-1157. https://doi.org/10.1111/j.1440-1746.2005.03832.x
  108. Kim JH, Cheon JH, Kim WH. The frequency and the course of the adverse effects of azathioprine/6-mercaptopurine treatment in patients with inflammatory bowel disease. Korean J Gastroenterol 2008;51:291-297.
  109. Jun JB, Cho DY, Kang C, Bae SC. Thiopurine S-methyltransferase polymorphisms and the relationship between the mutant alleles and the adverse effects in systemic lupus erythematosus patients taking azathioprine. Clin Exp Rheumatol 2005;23:873-876.
  110. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641-1657. https://doi.org/10.1016/S0140-6736(07)60751-X
  111. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861-1874. https://doi.org/10.1016/S0140-6736(07)60784-3
  112. Olaussen RW, Karlsson MR, Lundin KE, Jahnsen J, Brandtzaeg P, Farstad IN. Reduced chemokine receptor 9 on intraepithelial lymphocytes in celiac disease suggests persistent epithelial activation. Gastroenterology 2007;132:2371-2382. https://doi.org/10.1053/j.gastro.2007.04.023
  113. Salmi M, Jalkanen S. Developmental regulation of the adhesive and enzymatic activity of vascular adhesion protein-1 (VAP-1) in humans. Blood 2006;108:1555-1561. https://doi.org/10.1182/blood-2005-11-4599
  114. Silverman J, Liu Q, Bakker A, et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol 2005;23:1556-1561. https://doi.org/10.1038/nbt1166
  115. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53 Suppl 5:V1-V16.
  116. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB. AGA technical review on perianal Crohn's disease. Gastroenterology 2003;125:1508-1530. https://doi.org/10.1016/j.gastro.2003.08.025
  117. Hurst RD, Molinari M, Chung TP, Rubin M, Michelassi F. Prospective study of the features, indications, and surgical treatment in 513 consecutive patients affected by Crohn's disease. Surgery 1997;122:661-667. https://doi.org/10.1016/S0039-6060(97)90071-4
  118. Michelassi F, Block GE. Surgical management of Crohn's disease. Adv Surg 1993;26:307-322.
  119. Prantera C. Indications for surgery in Crohn's disease. Am J Gastroenterol 1990;85:900-901.
  120. Broe PJ, Bayless TM, Cameron JL. Crohn's disease: are enteroenteral fistulas an indication for surgery? Surgery 1982;91:249-253.
  121. Ribeiro MB, Greenstein AJ, Yamazaki Y, Aufses AH Jr. Intra-abdominal abscess in regional enteritis. Ann Surg 1991;213:32-36. https://doi.org/10.1097/00000658-199101000-00006
  122. Gardiner KR, Dasari BV. Operative management of small bowel Crohn's disease. Surg Clin North Am 2007;87:587-610. https://doi.org/10.1016/j.suc.2007.03.011
  123. Kim DH, Cheon JH, Moon CM, et al. Clinical efficacy of nonsurgical treatment of Crohn's disease-related intraabdominal abscess. Korean J Gastroenterol 2009;53:29-35.
  124. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000;231:38-45. https://doi.org/10.1097/00000658-200001000-00006
  125. Kim CG, Kim JW, Kim HD, et al. Clinical features of Crohn's disease in Korea. Korean J Gastroenterol 2002;40:173-180.
  126. Kim HA, Chung SS, Kim KH, Lee RA. The change of the clinical features that Crohn's disease treated by surgery. J Korean Surg Soc 2005;69:135-138.
  127. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000;95:1263-1276. https://doi.org/10.1111/j.1572-0241.2000.01940.x
  128. Stein RB, Hanauer SB. Medical therapy for inflammatory bowel disease. Gastroenterol Clin North Am 1999;28:297-321. https://doi.org/10.1016/S0889-8553(05)70058-3
  129. Campieri M, Lanfranchi GA, Bazzocchi G, et al. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet 1981;2:270-271.
  130. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997;40:775-781. https://doi.org/10.1136/gut.40.6.775
  131. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997;92:1867-1871.
  132. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a populationbased study. Gastroenterology 2001;121:255-260. https://doi.org/10.1053/gast.2001.26279
  133. Lee DH, Lee JH, Park DY, et al. Experience of cyclosporine A therapy in severe ulcerative colitis refractory to steroid treatment. Korean J Gastroenterol 1997;30:58-65.
  134. Chung GE, Cheon JH, Lee JY, et al. Efficacy of combination of intravenous cyclosporin A and steroid therapy versus prolonged intravenous steroid therapy alone in patients with severe ulcerative colitis refractory to initial intravenous steroid therapy. Korean J Gastroenterol 2006;48:263-268.
  135. Hanauer S, Good LI, Goodman MW, et al. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol 2000;95:1749-1754. https://doi.org/10.1111/j.1572-0241.2000.02185.x
  136. d'Albasio G, Paoluzi P, Campieri M, et al. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group. Am J Gastroenterol 1998;93:799-803.
  137. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-2476. https://doi.org/10.1056/NEJMoa050516
  138. Berger M, Gribetz D, Korelitz BI. Growth retardation in children with ulcerative colitis: the effect of medical and surgical therapy. Pediatrics 1975;55:459-467.
  139. Gumaste V, Sachar DB, Greenstein AJ. Benign and malignant colorectal strictures in ulcerative colitis. Gut 1992;33:938-941. https://doi.org/10.1136/gut.33.7.938
  140. Cohen JL, Strong SA, Hyman NH, et al. Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum 2005;48:1997-2009. https://doi.org/10.1007/s10350-005-0180-z
  141. Park IJ, Yu CS, Kim HC, et al. Analysis of pouchitis after restorative proctocolectomy. Korean J Gastroenterol 2005;46:99-104.
  142. Moum B, Ekbom A, Vatn MH, et al. Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease: results of a large, prospective population-based study in southeastern Norway, 1990-93. Scand J Gastroenterol 1997;32:1005-1012. https://doi.org/10.3109/00365529709011217
  143. Leijonmarck CE, Persson PG, Hellers G. Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study. Gut 1990;31:329-333. https://doi.org/10.1136/gut.31.3.329
  144. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994;107:3-11.
  145. Sinclair TS, Brunt PW, Mowat NA. Nonspecific proctocolitis in northeastern Scotland: a community study. Gastroenterology 1983;85:1-11.
  146. Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis: a long-term follow-up of 1116 patients. Dig Dis Sci 1993;38:1137-1146. https://doi.org/10.1007/BF01295733
  147. Hendriksen C, Kreiner S, Binder V. Long term prognosis in ulcerative colitis: based on results from a regional patient group from the county of Copenhagen. Gut 1985;26:158-163. https://doi.org/10.1136/gut.26.2.158

Cited by

  1. Relationships between genetic polymorphisms of triggering receptor expressed on myeloid cells-1 and inflammatory bowel diseases in the Korean population vol.89, pp.9, 2010, https://doi.org/10.1016/j.lfs.2011.06.018
  2. Inflammatory Bowel Disease in Pediatric Age vol.14, pp.suppl1, 2010, https://doi.org/10.5223/kjpgn.2011.14.suppl1.s34
  3. Increasing Incidence of Inflammatory Bowel Disease Among Young Men in Korea Between 2003 and 2008 vol.56, pp.4, 2010, https://doi.org/10.1007/s10620-010-1403-2
  4. Outcome Predictors for Thiopurine Maintenance Therapy in Patients with Crohn’s Disease vol.57, pp.1, 2010, https://doi.org/10.1007/s10620-011-1955-9
  5. Recurrent Acute Pericarditis Induced by 5-aminosalicylates in a Patient with Inflammatory Bowel Disease vol.10, pp.3, 2010, https://doi.org/10.5217/ir.2012.10.3.289
  6. Baicalein, an active component of Scutellaria baicalensis Georgi, induces apoptosis in human colon cancer cells and prevents AOM/DSS-induced colon cancer in mice vol.43, pp.5, 2010, https://doi.org/10.3892/ijo.2013.2086
  7. Interleukin-17 in the Inflammatory Bowel Disease vol.33, pp.1, 2010, https://doi.org/10.7599/hmr.2013.33.1.27
  8. Exposure to Diagnostic Radiation in Patients with Inflammatory Bowel Disease: A Single Center Study vol.11, pp.2, 2010, https://doi.org/10.5217/ir.2013.11.2.107
  9. Genome-wide association study of Crohn's disease in Koreans revealed three new susceptibility loci and common attributes of genetic susceptibility across ethnic populations vol.63, pp.1, 2010, https://doi.org/10.1136/gutjnl-2013-305193
  10. Efficacy of early immunomodulator therapy on the outcomes of Crohn’s disease vol.14, pp.None, 2010, https://doi.org/10.1186/1471-230x-14-85
  11. Effect of Follow-Up Endoscopy on the Outcomes of Patients with Inflammatory Bowel Disease vol.59, pp.10, 2010, https://doi.org/10.1007/s10620-014-3197-0
  12. Does Endoscopic Assessment of Mucosal Healing Affect IBD Management? vol.59, pp.10, 2010, https://doi.org/10.1007/s10620-014-3311-3
  13. Differences in the Adverse Effects of Azathioprine between Inflammatory Bowel Disease and Autoimmune Hepatitis in Korean Patients vol.64, pp.6, 2014, https://doi.org/10.4166/kjg.2014.64.6.348
  14. The clinical characteristics of patients with free perforation in Korean Crohn’s disease: results from the CONNECT study vol.15, pp.None, 2010, https://doi.org/10.1186/s12876-015-0262-x
  15. Immunochip Analysis Identification of 6 Additional Susceptibility Loci for Crohnʼs Disease in Koreans : vol.21, pp.1, 2010, https://doi.org/10.1097/mib.0000000000000268
  16. Genetic association of apolipoprotein E polymorphisms with inflammatory bowel disease vol.21, pp.3, 2010, https://doi.org/10.3748/wjg.v21.i3.897
  17. Balancing my disease: women's perspectives of living with inflammatory bowel disease vol.24, pp.15, 2015, https://doi.org/10.1111/jocn.12785
  18. Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study vol.9, pp.5, 2010, https://doi.org/10.5009/gnl14120
  19. Clinical Factors and Disease Course Related to Diagnostic Delay in Korean Crohn’s Disease Patients: Results from the CONNECT Study vol.10, pp.12, 2015, https://doi.org/10.1371/journal.pone.0144390
  20. Efficacy of Adalimumab in Korean Patients with Crohn’s Disease vol.10, pp.2, 2016, https://doi.org/10.5009/gnl15165
  21. Factors Associated with Anxiety and Depression in Korean Patients with Inactive Inflammatory Bowel Disease vol.10, pp.3, 2016, https://doi.org/10.5009/gnl15188
  22. Deep resequencing of 131 Crohn's disease associated genes in pooled DNA confirmed three reported variants and identified eight novel variants vol.65, pp.5, 2010, https://doi.org/10.1136/gutjnl-2014-308617
  23. Effectiveness of a Turbo Direction Change for Reduction of Motion Artifact in Magnetic Resonance Enterography vol.21, pp.3, 2010, https://doi.org/10.4283/jmag.2016.21.3.421
  24. Development of a Novel Predictive Model for the Clinical Course of Crohnʼs Disease : Results from the CONNECT Study vol.23, pp.7, 2017, https://doi.org/10.1097/mib.0000000000001106
  25. Association of Perianal Fistulas with Clinical Features and Prognosis of Crohn’s Disease in Korea: Results from the CONNECT Study vol.12, pp.5, 2010, https://doi.org/10.5009/gnl18157
  26. Total Glycosides of Peony Protects Against Inflammatory Bowel Disease by Regulating IL-23/IL-17 Axis and Th17/Treg Balance vol.47, pp.1, 2010, https://doi.org/10.1142/s0192415x19500095
  27. Effect of Age on the Initiation of Biologic Agent Therapy in Patients With Inflammatory Bowel Disease: Korean Common Data Model Cohort Study vol.8, pp.4, 2010, https://doi.org/10.2196/15124
  28. Effect of Thiopurine on Potential Surgical Intervention in Crohn’s Disease in Korea: Results from the CONNECT Study vol.10, pp.1, 2021, https://doi.org/10.3390/jcm10010025
  29. Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study vol.19, pp.1, 2010, https://doi.org/10.5217/ir.2019.09160
  30. Epidemiology and diagnosis of inflammatory bowel diseases vol.64, pp.9, 2010, https://doi.org/10.5124/jkma.2021.64.9.579